Michael McGarvey, MD
Vascular Neurology · Philadelphia, PANPI 1154355865
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,250 of the $15,327 with a category attached, or 73.4%. Medtronic accounts for 99.8% of it on its own, with 1 other manufacturer making up the rest. Among vascular neurology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $729.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- TG Therapeutics, Inc.$25
Across 1 payment — averaging $56,148 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$56K
What the payments were for
- Speaking & faculty fees$11,25073%
- Travel & lodging$3,81225%
- Food & beverage$2652%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $15,302 |
| TG Therapeutics, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pipeline$3,733
How this compares
$15,327 in reported general payments places this provider in the 90th percentile of 52 vascular neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $107,276 |
| Levetiracetam | 38 | $1,625 |
| Gabapentin | 20 | $297 |
| Sertraline Hcl | 16 | $244 |
| Escitalopram Oxalate | 21 | $141 |
| Atorvastatin Calcium | 15 | $128 |
| Clonazepam | 11 | $10 |
| Lorazepam | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Philadelphia
- Scott KasnerPhiladelphia$210K
- Steven MessePhiladelphia$14K
- Donna GeorgePhiladelphia$4K
- Brett CucchiaraPhiladelphia$2K
- Sydni ColePhiladelphia$408
- Paul NovelloPhiladelphia$122
- Christopher FavillaPhiladelphia$109
- Kelley HumbertPhiladelphia$85
- Qingyang YuanPhiladelphia$79
- Laura SteinPhiladelphia$64
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.